21st April 2022 – Inflexion announces investment into Upperton Inflexion is pleased to announce it has made a substantial investment into Upperton Pharma Solutions (“Upperton”), a UK-based specialist contract development and manufacturing organisation (“CDMO”) which has expertise in particle engineering for the pharmaceutical industry. Inflexion has invested alongside the founder and the management team who … Read more
5th April 2022 – Upperton Pharma Solutions launches nasal delivery development platform Nottingham-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions, has launched a unique nasal delivery development platform, UpperNose™, to make it easier and faster for small and mid-sized innovators to access the knowledge and capabilities necessary for the successful development of nasal … Read more
Growing Interest in Nasal Delivery Recent trends have seen growing interest in exploiting nasal delivery as a means of delivering a wide range of drugs including small molecules and larger biologics for a wide range of indications. The nasal cavity is already a well-established delivery route capable of achieving rapid and high level of drug … Read more
Upperton Adds New Nasal and Oral Delivery Technologies Upperton is pleased to announce that it has bolstered its nasal and oral delivery capabilities with the addition of a number of new analytical and formulation technologies. Nasal Delivery News – Upperton enhances its analytical capabilities by acquiring next generation nasal particle impaction technology Upperton has acquired the … Read more
What’s New In 2022: Exciting Plans For Upperton Pharma Solutions! Happy New Year to all of our customers and our friends across the industry! There is no doubt that 2021 was a challenging year for everyone in one way or another, but its fair to say that it was also a year of progress and … Read more
Article 20th May 2021 – Upperton Nasal Delivery Article Published in ONdrugDelivery Formulation Options In Nasal Drug Delivery Upperton had an article published in Edition 119 ONdrugDeliver in May 2021 In the article Richard Johnson, CEO and founder of Upperton, discusses the advantages of nasal delivery and why there is growing interest in this route … Read more
News 29th April 2021 – Formulation Options in Nasal Drug Delivery Nasal delivery offers a number of unique opportunities for the successful delivery of drugs and vaccines either locally, systemically or directly to the central nervous system. This utility has resulted in growing interest from scientists looking to administer both therapeutic agents and vaccines via … Read more
News 25th March 2021 – Formulation Options in Nasal Drug Delivery The anatomy and physiology of the nasal cavity creates a number of unique opportunities for the successful delivery of drugs and vaccines. This can be locally, systemically or directly to the central nervous system. This utility has resulted in growing interest from scientists looking to … Read more
News 11th March 2021 – Nasal Delivery of Therapeutics and Vaccines The anatomy and physiology of the nasal cavity creates a number of unique opportunities for the successful delivery of drugs and vaccines. This can be locally, systemically or directly to the central nervous system. This utility has resulted in growing interest from scientists looking … Read more
News 15th December 2020 – Season’s Greetings and End of Year Review Season’s Greetings and a Happy New Year to all of our Customers and our industry contacts from everyone at Upperton Pharma Solutions! Once again, we head towards the year-end holiday break with the Upperton team continuing to work at full capacity to ensure … Read more
Upperton Pharma Solutions is an early phase Pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with more than twenty years of experience in the development of pharmaceutical dosage forms.
Albert Einstein Centre, Nottingham Science Park, Nottingham, UK NG7 2TN,
Phone: +44 (0) 115 855 7050
Email: contact@upperton.com